Design Module
The Design Module contains detailed information about the study design, including study type, allocation methods, intervention models, masking information, primary purpose, enrollment details, and biospecimen information. This module provides essential details about how the clinical trial is structured and conducted.
Design Module path is as follows:
Study -> Protocol Section -> Design Module
Design Module
Ignite Creation Date:
2025-12-24 @ 5:19 PM
Ignite Modification Date:
2025-12-24 @ 5:19 PM
NCT ID:
NCT02289950
Study Type:
INTERVENTIONAL
Allocation:
RANDOMIZED
Primary Purpose:
TREATMENT
Study:
NCT02289950
Study Brief:
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Protocol Section:
NCT02289950
Bio Specs (If Any):
Design Masking Infos (If Any):
Design Masking Infos
| Design Masking Brief | View |
|---|---|
| None | View |
Design Observational Models (If Any):
Design Time Perspectives (If Any):
Design Who Masked (If Any):
Enrollment Infos (If Any):
Enrollment Infos
| Enrollment Type | Enrollment Count | View |
|---|---|---|
| ACTUAL | 332 | View |
Expanded Access Types (If Any):
Phases (If Any):
Phases
| Phase Brief | Phase Text | View |
|---|---|---|
| None | PHASE2 | View |